Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder

Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder

A John Rush;Helena C Kraemer;Harold A Sackeim;Maurizio Fava;Madhukar H Trivedi;Ellen Frank;Philip T Ninan;Michael E Thase;Alan J Gelenberg;David J Kupfer;Darrel A Regier;Jerrold F Rosenbaum;Oakley Ray;Alan F Schatzberg;A John Rush;Helena C Kraemer;Harold A Sackeim;Maurizio Fava;Madhukar H Trivedi;Ellen Frank;Philip T Ninan;Michael E Thase;Alan J Gelenberg;David J Kupfer;Darrel A Regier;Jerrold F Rosenbaum;Oakley Ray;Alan F Schatzberg;
neuropsychopharmacology : official publication of the american college of neuropsychopharmacology 2006 Vol. 31 pp. 1841-1853
260
rush2006neuropsychopharmacologyreport

Abstract

This report summarizes recommendations from the ACNP Task Force on the conceptualization of remission and its implications for defining recovery, relapse, recurrence, and response for clinical investigators and practicing clinicians. Given the strong implications of remission for better function and a better prognosis, remission is a valid, clinically relevant end point for both practitioners and investigators. Not all depressed patients, however, will reach remission. Response is a less desirable primary outcome in trials because it depends highly on the initial (often single) baseline measure of symptom severity. It is recommended that remission be ascribed after 3 consecutive weeks during which minimal symptom status (absence of both sadness and reduced interest/pleasure along with the presence of fewer than three of the remaining seven DSM-IV-TR diagnostic criterion symptoms) is maintained. Once achieved, remission can only be lost if followed by a relapse. Recovery is ascribed after at least 4 months following the onset of remission, during which a relapse has not occurred. Recovery, once achieved, can only be lost if followed by a recurrence. Day-to-day functioning and quality of life are important secondary end points, but they were not included in the proposed definitions of response, remission, recovery, relapse, or recurrence. These recommendations suggest that symptom ratings that measure all nine criterion symptom domains to define a major depressive episode are preferred as they provide a more certain ascertainment of remission. These recommendations were based largely on logic, the need for internal consistency, and clinical experience owing to the lack of empirical evidence to test these concepts. Research to evaluate these recommendations empirically is needed.

Citation

ID: 120111
Ref Key: rush2006neuropsychopharmacologyreport
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
120111
Unique Identifier:
doi:10.1038/sj.npp.1301131
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet